Antibodies against Ebola
Antibodies produced using the vivoXPRESS® biopharmaceutical manufacturing system have been shown to neutralize the Sudan strain of Ebola as well as antibodies produced using other systems, according to analyses performed by the U.S. Army Medical Research Institute of Infectious Diseases (USAMRIID) with funding support and technical advisory services from the National Research Council of Canada Industrial Research Assistance Program (NRC-IRAP).
Building upon the USAMRIID project, our team worked with University of New Mexico scientists to advance Ebola research and improve existing vaccines by inducing more effective immune responses to infection. The project employed the vivoXPRESS® system to express glycoproteins found on Filoviridae, the family of viruses that cause Ebola and Marburg disease, two severe and often fatal viral hemorrhagic fevers that afflict humans and non-human primates.